{rfName}
So

Indexed in

License and use

Citations

22

Altmetrics

Grant support

We thank Ramon M. Pujol, Salvador Aznar-Benitah and Christian Hafner for critical review of prior versions of this paper. This work was supported, in part, by grants from Plan Nacional de I+D (SAF2007-60860 and Consolider ONCOBIO), Ministerio de Ciencia e Innovacion, Madrid, Spain.

Analysis of institutional authors

Toll, AgustiCorresponding Author

Share

June 5, 2025
Publications
>
Review
No

Somatic oncogenic mutations, benign skin lesions and cancer progression: Where to look next?

Publicated to:Cell Cycle. 7 (17): 2674-2681 - 2008-09-01 7(17), DOI: 10.4161/cc.7.17.6523

Authors: Toll, Agusti; Real, Francisco X

Affiliations

CNIO, Epithelial Carcinogenesis Grp, Programa Patol Mol, Madrid, Spain - Author
Hosp Mar, Dept Dermatol, Barcelona 08003, Spain - Author
Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain - Author

Abstract

Somatic oncogenic activating mutations in FGFR3 and/or PIK3CA have recently been described in benign epithelial cutaneous lesions that never progress to malignancy (seborrheic keratoses and epidermal nevi). The same mutations have been observed in malignant neoplasms from other tissues (bladder carcinoma, cervix cancer, colorectal cancer, myeloma). However, many of the above-mentioned epithelial benign cutaneous tumors do not harbour mutations in FGFR3 or PIK3CA. In this review, we focus on new candidate genes for discovery and we outline the potential of the skin as a model to achieve a better understanding of cancer biology.

Keywords

acanthosis nigricansbenignc-ha-rasepidermal neviepidermal nevusfgfr3fgfr3 mutationsmalignant cutaneous lesionsmosaicismmutationsoncogenepik3caproteus-syndromeseborrheic keratosesskintransplant recipientstumor-suppressorAcanthosis nigricansBenignC-ha-rasEpidermal neviEpidermal nevusFgfr3Fgfr3 mutationsMalignant cutaneous lesionsMosaicismMutationsOncogenePik3caProteus-syndromeSeborrheic keratosesSkiSkinSquamous-cell carcinomaTransplant recipientTransplant recipientsTumor-suppressor

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Cell Cycle due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2008, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category . Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-17:

  • WoS: 11

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-17:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 15 (PlumX).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Toll Abelló, Agustín) .

the author responsible for correspondence tasks has been Toll Abelló, Agustín.